Skip to main content
. 2019 Jun 4;10(38):3667–3680.

Figure 3. Eribulin in combination with BKM120 inhibits tumor growth in TNBC PDXs.

Figure 3

Tumor volume changes with time compared to baseline following treatment with either vehicle, eribulin (1 mg/kg, IP, day 1 each week x 3), BKM120 (30 mg/kg, PO, days 1-5 each week x3) or the combination of eribulin and BKM120 in (A) WHIM6, (B) WHIM12 and (C) WHIM21 TNBC PDX models in vivo (n=6). (D) Tumor volume changes with time compared to baseline following treatment with either eribulin (0.3 mg/kg, IP, day 1 each week x 3), or the combination of eribulin and BKM120 administered concurrently (eribulin 0.3 mg/kg, IP, day 1 and BKM120 30 mg/kg, PO, days 1-5 each week) or sequentially (eribulin 0.3 mg/kg, IP, day 1 followed by BKM120 30 mg/kg, PO, on days 2-5 each week) in WHIM21. * indicates p<0.05 and **** indicates p<0.0001.